Table 1 Clinical characteristics of the patients
Characteristic | ORH | MLRH | p-value |
|---|---|---|---|
Total | 336 | 302 | Â |
Patients lost to follow-up (n) | 15 | 11 | Â |
Patients followed up with (n) | 321 | 291 | 0.016 |
Age (y) | 48.55 ± 8.51 | 46.92 ± 8.10 |  |
BMI (kg/m2) | 23.39 ± 2.98 | 23.20 ± 3.15 | 0.442 |
Histological grading (%) | Â | Â | 0.146 |
 G1 | 23 (7.2) | 45 (15.5) |  |
 G2 | 173 (53.9) | 136 (46.7) |  |
 G3 | 125 (38.9) | 110 (37.8) |  |
Pathological type (%) | Â | Â | 0.700 |
 Squamous cell carcinoma | 262 (81.6) | 233 (80.1) |  |
 Adenocarcinoma | 55 (17.1) | 52 (17.9) |  |
 Adenosquamous carcinoma | 4 (1.2) | 6 (2.1) |  |
FIGO stage (%) | Â | Â | < 0.001 |
 IB1 | 265 (82.6) | 269 (92.4) |  |
 IIA1 | 56 (17.4) | 22 (7.6) |  |
Tumor diameter (%) | Â | Â | 0.079 |
 < 2 cm | 87 (27.1) | 98 (33.7) |  |
 2~4 cm | 234 (72.9) | 193 (66.3) |  |
Invasion depth (%) | Â | Â | 0.001 |
 Inner 1/3 | 119 (37.1) | 142 (48.8) |  |
 Middle 1/3 | 116 (36.1) | 97 (33.3) |  |
 Deep 1/3 | 86 (26.8) | 52 (17.9) |  |
Vascular tumor embolus (%) | Â | Â | 0.325 |
 Negative | 243 (75.7) | 230 (79.0) |  |
 Positive | 78 (24.3) | 61 (21.0) |  |
Lymph node metastasis (%) | Â | Â | 0.143 |
 Negative | 258 (80.4) | 247 (84.9) |  |
 Positive | 63 (19.6) | 44 (15.1) |  |
Adjuvant therapy (%) | Â | Â | 0.058 |
 None | 163 (50.8) | 179 (61.5) |  |
 Radiotherapy | 35 (10.9) | 28 (9.6) |  |
 Chemotherapy | 22 (6.9) | 14 (4.8) |  |
 CCRT | 101 (31.5) | 70 (24.1) |  |